The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.45
Bid: 17.80
Ask: 18.95
Change: 0.00 (0.00%)
Spread: 1.15 (6.461%)
Open: 18.45
High: 0.00
Low: 0.00
Prev. Close: 18.45
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update and Appointment of Chairman

18 Nov 2014 07:00

RNS Number : 2669X
BATM Advanced Communications Ld
18 November 2014
 



18 November 2014

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Business Update and Appointment of Chairman

 

BATM Advanced Communications Limited (LSE: BVC; TASE: BATM), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update on trading and announces the appointment of Dr. Gideon Chitayat, the current Vice-Chairman of the Group, as Chairman of the Group following the previously stated retirement of Peter Sheldon, Chairman, at the end of this year. Dr. Chitayat will assume his post on 1 January 2015.

 

Business Update

 

As noted in the Group's interim results, the momentum of the first half of 2014 in the Medical division has been maintained into the second half of the year. However, the Telecom division has suffered from a longer-than-anticipated sales cycle as it continues to rebuild and implement its new strategy of focusing on Tier 1 customers.

 

In the Medical division, the Distribution unit has continued to grow revenues organically in all territories. The Pathogenic Waste Treatment Sterilisation unit has launched a new version of a smaller sterilizer designed for dialysis centres and laboratories. The Group has already received several orders for the new sterilizer, and will supply 40 devices by the end of the year. The Diagnostics unit is installing additional equipment to expand production capacity to meet the anticipated growth in demand. The installation is scheduled to complete during the first quarter of 2015 and is expected to enable production capacity to almost double in 2015. As the Diagnostics and Pathogenic Waste Treatment Sterilisations units continue to grow, the Medical division is expected to be the main driver of Group revenues over the next six to 12 months.

 

The Telecom division remains focused on the new strategy of concentrating mainly on Tier 1 clients, SDN (Software Driven Networks) and NFV (Network Functions Virtualization). This has brought its challenges as the sales cycle has been slightly longer than anticipated and, consequently, it has not served to offset the previously-stated decline in sales of end-of-life products as expected. The division is, however, beginning to experience positive momentum. As announced today, it has been awarded a contract, worth approximately $2m, by a major mobile network operator in the Asia Pacific region to provide services, in 2014 and 2015, as part of its large-scale network modernization that will deliver 4G/LTE services to an expanding subscriber base. BATM is expected to benefit from increasing demand in 2015 as the market transitions to these technologies. The Group also signed a joint collaboration and marketing agreement with Oracle, and is already in discussions with several potential customers, which it believes will be material to the growth of BATM in 2015 and beyond. As a result, whilst revenues in the Telecoms division will be lower in 2014 compared with the previous year, the Group expects to return to growth in 2015.

  

As a result, BATM expects that revenues and profit for the full year 2014 will be slightly lower compared with 2013 and below market expectations. The Group's balance sheet and cash position remain strong.

 

Appointment of Chairman

 

BATM is pleased to announce the appointment of Dr. Gideon Chitayat as Chairman of the Group with immediate effect. Dr. Chitayat replaces Peter Sheldon who retires from his position as Chairman and as a non-executive director of BATM. Dr. Chitayat joined the Board of BATM as a non-executive director in June 2010 and has served as Vice-Chairman since 2012.

 

Peter Sheldon, Chairman of BATM, said: "I am proud to have headed a company that has not only survived the gyrations that have seen many companies disappear but one that has been able to rebase its activities to provide a platform that promises greater stability and renewed growth. My colleagues on the Board of BATM have been a great support and I thank them for that. I thank, also, our shareholders who have placed their confidence in the Group over many years. I am delighted that Gideon has been chosen to be my successor. He will help to ensure that BATM will fulfil the expectations that our patient shareholders have every reason to expect and which our current business strategy is designed to deliver."

 

Dr. Zvi Marom, Chief Executive Officer of BATM, said: "On behalf of the management team, the employees of the Group and me personally, I would like to convey my heartfelt thanks to Peter for his energy, enthusiasm and vision. He has been a friend and tremendous counsel to us, chartinga course that has seen BATM become a major global business. We wish him all the best in his retirement. We are delighted to have some continuity and stability at the Board with the appointment of Dr. Gideon as our Chairman as the Group continues to rebuild its Telecom division whilst supporting the growth in the Medical division."

 

 

Enquiries

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

Ofer Barner, Chief Financial Officer

+972 9866 2525

finnCap

Stuart Andrews, Henrik Persson

+44 20 7220 0500

Shore Capital

Pascal Keane

+44 20 7408 4090 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBURRSAAAAUA
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.